Compare Inovio Pharmaceuticals Inc (INO) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Tencent Music Entertainment Group - ADR trades at $8.94 (market cap $15.08B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 168.9× Inovio Pharmaceuticals Inc's market cap, and Tencent Music Entertainment Group - ADR pays a 2.62% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | TME | |
|---|---|---|
Market Cap | $89.27M | $15.08B |
Sector | Health | Media |
52-Week High | $2.87 | $26.36 |
52-Week Low | $1.05 | $8.16 |
Enterprise Value | $60.28M | $11.85B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
TME trades at $9.19, up 0.77% today, with a bullish technical signal from moving averages. The company reported strong 2025 results with revenue of $32.9B and net income of $11.1B, though recent quarterly earnings have missed expectations. Analyst consensus is mixed with 45.8% buy ratings and a $14 price target, while cash flow trends show significant investment activity.
The outlook remains cautiously optimistic with solid profitability metrics and ecosystem expansion through initiatives like SEND audio technology. Key risks include competitive pressures and execution challenges in premium content delivery. The stock presents value opportunity given reasonable valuation multiples relative to earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
